We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.71B
AUM Growth
-$646M
Cap. Flow
+$138M
Cap. Flow %
3.73%
Top 10 Hldgs %
52.04%
Holding
130
New
26
Increased
23
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$76.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.9M
3
FOLD
Amicus Therapeutics
FOLD
+$33.6M
4
AMRN
Amarin Corp
AMRN
+$25M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$21.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$54.5M
2
ARRY
Array Biopharma Inc
ARRY
+$48.1M
3
BPMC
Blueprint Medicines
BPMC
+$28.5M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$24M
5
QURE icon
uniQure
QURE
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 93.8%
2 Financials 0.46%
3 Consumer Discretionary 0.18%
4 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGRX
51
DELISTED
Agile Therapeutics
AGRX
$12.7M 0.34%
5,363
+1,150
+27% +$2.83M
MORF
52
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$11.8M 0.32%
650,000
– –
TXG icon
53
10x Genomics
TXG
$5.86B
$11.1M 0.3%
+220,000
New +$12.2M
SCPE.U
54
DELISTED
SC Health Corporation Units, each consisting of one Class A ordinary share, $0.0001 par value, and o
SCPE.U
$10.3M 0.28%
+1,000,000
New +$10.3M
MRKR icon
55
Marker Therapeutics
MRKR
$18.7M
$10.2M 0.28%
200,000
– –
IDYA icon
56
IDEAYA Biosciences
IDYA
$3.43B
$9.58M 0.26%
1,141,484
– –
ADPT icon
57
Adaptive Biotechnologies
ADPT
$3.61B
$9.12M 0.25%
295,000
+10,000
+4% +$408K
MOTS
58
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$8.34M 0.22%
14,035
– –
CBAY
59
DELISTED
Cymabay Therapeutics
CBAY
$7.78M 0.21%
1,520,355
-2,342,466
-61% -$14.2M
LITS
60
Lite Strategy Inc
LITS
$32.1M
$7.39M 0.2%
220,022
– –
ALEC icon
61
Alector
ALEC
$169M
$7.38M 0.2%
511,731
– –
VRAY
62
DELISTED
ViewRay, Inc.
VRAY
$7.11M 0.19%
2,451,748
-3,003,495
-55% -$17.8M
ZBH icon
63
Zimmer Biomet
ZBH
$18.8B
$6.86M 0.18%
+51,500
New +$6.65M
HCAT icon
64
Health Catalyst
HCAT
$160M
$6.67M 0.18%
+210,924
New +$8.3M
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$6.48M 0.17%
97,600
– –
ORTX
66
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$6.2M 0.17%
52,180
– –
SIC
67
DELISTED
Select Interior Concepts, Inc. Class A Common Stock
SIC
$5.71M 0.15%
+440,000
New +$5.2M
PRVB
68
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$4.55M 0.12%
+666,322
New +$6.74M
CERN
69
DELISTED
Cerner Corp
CERN
$4.43M 0.12%
+65,000
New +$4.6M
TBIO
70
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.31M 0.12%
435,000
– –
HSACU
71
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
$4.29M 0.12%
400,000
– –
ATEC icon
72
Alphatec Holdings
ATEC
$1.48B
$4.27M 0.12%
+850,000
New +$4.42M
FULC icon
73
Fulcrum Therapeutics
FULC
$240M
$3.98M 0.11%
+600,000
New +$6.64M
VERU icon
74
Veru
VERU
$35.5M
$3.56M 0.1%
165,000
+20,500
+14% +$427K
TWST icon
75
Twist Bioscience
TWST
$5.31B
$3.48M 0.09%
145,856
+35,000
+32% +$1.02M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Perceptive Advisors held 130 positions worth $3.71B, down 15% from $4.36B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Perceptive Advisors deployed $138M of net new capital in Q3 2019, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Blueprint Medicines, an estimated $28.5M trimmed.

  • Perceptive Advisors's largest Q3 2019 buy was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $38.9M increase.
  • Perceptive Advisors's biggest Q3 2019 reduction was Blueprint Medicines, cutting an estimated $28.5M.
  • Perceptive Advisors fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $54.5M.
  • Perceptive Advisors's ten largest holdings make up 52% of its $3.71B portfolio in Q3 2019.
  • Perceptive Advisors opened 26 new positions and closed 21 in Q3 2019.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $3.71B.

Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.